Leuven, Belgium – July 23, 2019 – miDiagnostics today announced it has joined the NVIDIA Inception program, which is designed to nurture startups revolutionizing industries with advancements in AI and data sciences.
miDiagnostics is developing a new class of near-patient diagnostic platform based on silicon chips that are embedded in credit card-sized test cards. These silicon chips, called nanoFluidic Processors, can be functionalized to allow for the measurement of virtually any type of biomarker: cells, proteins, nucleic acids and small molecules. The test cards are read by a compact reader for rapid data collection and analysis, outside a laboratory environment, by means of advanced machine learning algorithms.
“We are very excited to be included in this inception program. By tapping into the vast algorithmic know-how and exceptional computational optimization expertise offered by the NVIDIA ecosystem and Inception program, we can further accelerate our software R&D programs. In addition, it will allow us to increase the maturity of our current algorithmic solutions to a commercial-grade level,” Jan Fransens, Director of Algorithms and Software, comments.
NVIDIA’s Inception program is a virtual accelerator program that helps startups during critical stages of product development, prototyping and deployment. Every Inception member gets a custom set of ongoing benefits, from hardware grants and marketing support to training with deep learning experts.
miDiagnostics was founded in 2015 as a spin-off from imec (Leuven, Belgium), a world-leading research and innovation hub in nano-electronics and digital technologies, and it has a research collaboration with the Johns Hopkins University (Baltimore, USA), a world-renowned medical research institute. Following a Series A round of €60 million, led by Alychlo, Pamica and PMV, miDiagnostics was incorporated to further build on the extensive research, and scientific and clinical expertise of these two institutes.
Contact about this news:
Marijke Van der Auwera